CD19/CD22 and CD19/CD123 dual CAR T-cells for ALL have been successfully constructed and show greater potency than single CAR T-cells or a pool of both CAR T-cells in mice (40, 130, 168). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.